Results from the phase 3 evERA Breast Cancer study in the New England Journal of Medicine show that adding giredestrant to the mTOR inhibitor everolimus nearly doubles survival without progression in metastatic breast cancer. The all-oral combination delivered a clinically meaningful extension of time on therapy endpoints versus control. The data place an endocrine pathway degrader strategy alongside established mTOR combinations, targeting a population where resistance to standard therapies remains a persistent challenge. Clinicians will now weigh efficacy signals against tolerability and patient selection considerations for real-world use. The trial’s publication in a leading journal is likely to accelerate downstream discussions around sequencing with CDK4/6 inhibitors and fulvestrant-class options, particularly for hormone receptor–positive, HER2-negative disease.